Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Refinement of molecular approaches to improve the chance of identification of hematopoietic-restricted minor histocompatibility antigens.

de Rijke B, van Horssen-Zoetbrood A, Veenbergen S, Fredrix H, de Witte T, van de Wiel-van Kemenade E, Dolstra H.

J Immunol Methods. 2008 Jan 1;329(1-2):125-37. Epub 2007 Oct 26.

PMID:
17996247
2.

Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.

Levenga H, Woestenenk R, Schattenberg AV, Maas F, Jansen JH, Raymakers R, De Mulder PH, van de Wiel-van Kemenade E, Schaap N, de Witte T, Dolstra H.

Bone Marrow Transplant. 2007 Sep;40(6):585-92. Epub 2007 Jul 16.

PMID:
17637687
3.

A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

de Rijke B, van Horssen-Zoetbrood A, Beekman JM, Otterud B, Maas F, Woestenenk R, Kester M, Leppert M, Schattenberg AV, de Witte T, van de Wiel-van Kemenade E, Dolstra H.

J Clin Invest. 2005 Dec;115(12):3506-16.

4.

Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy.

de Rijke B, Fredrix H, Zoetbrood A, Scherpen F, Witteveen H, de Witte T, van de Wiel-Van Kemenade E, Dolstra H.

Blood. 2003 Oct 15;102(8):2885-91. Epub 2003 Jul 3.

5.

Monitoring of developing graft-versus-host disease mediated by herpes simplex virus thymidine kinase gene-transduced T cells.

Kolen S, Weijtens M, Hagenbeek A, van Spronsen A, Smulders S, de Weger R, de Witte T, Dolstra H, van de Wiel van Kemenade E, Martens A.

Hum Gene Ther. 2003 Mar 1;14(4):341-51.

PMID:
12659675
6.

Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms.

Maas F, Schaap N, Kolen S, Zoetbrood A, Buño I, Dolstra H, de Witte T, Schattenberg A, van de Wiel-van Kemenade E.

Leukemia. 2003 Mar;17(3):630-3. No abstract available. Erratum in: Leukemia. 2004 Mar;18(3):663.

PMID:
12646954
7.

Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms.

Maas F, Schaap N, Kolen S, Zoetbrood A, Buño I, Dolstra H, de Witte T, Schattenberg A, van de Wiel-van Kemenade E.

Leukemia. 2003 Mar;17(3):621-9. Erratum in: Leukemia. 2004 Mar;18(3):663.

PMID:
12646953
8.

Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes.

Dolstra H, de Rijke B, Fredrix H, Balas A, Maas F, Scherpen F, Aviles MJ, Vicario JL, Beekman NJ, Ossendorp F, de Witte TM, van de Wiel-van Kemenade E.

Eur J Immunol. 2002 Oct;32(10):2748-58.

9.

Biodistribution and retention time of retrovirally labeled T lymphocytes in mice is strongly influenced by the culture period before infusion.

Kolen S, Dolstra H, van de Locht L, Braakman E, Schattenberg A, de Witte T, van de Wiel-van Kemenade E.

J Immunother. 2002 Sep-Oct;25(5):385-95.

PMID:
12218776
10.

Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions.

Schaap N, Schattenberg A, Bär B, Preijers F, van de Wiel van Kemenade E, de Witte T.

Leukemia. 2001 Sep;15(9):1339-46.

PMID:
11516094
11.

TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells.

Dolstra H, Fredrix H, van der Meer A, de Witte T, Figdor C, van de Wiel-van Kemenade E.

Bone Marrow Transplant. 2001 May;27(10):1087-93.

12.

In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.

Schattenberg A, Schaap N, Van De Wiel-Van Kemenade E, Bär B, Preijers F, Van Der Maazen R, Roovers E, De Witte T.

Leuk Lymphoma. 1999 Jan;32(3-4):317-25.

PMID:
10037029
13.

A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.

Dolstra H, Fredrix H, Maas F, Coulie PG, Brasseur F, Mensink E, Adema GJ, de Witte TM, Figdor CG, van de Wiel-van Kemenade E.

J Exp Med. 1999 Jan 18;189(2):301-8.

14.

Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL.

Dolstra H, Fredrix H, Preijers F, Goulmy E, Figdor CG, de Witte TM, van de Wiel-van Kemenade E.

J Immunol. 1997 Jan 15;158(2):560-5.

PMID:
8992968
15.

[The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].

Schattenberg AV, van de Wiel-van Kemenade E, Bär BM, Geurts van Kessel AH, van der Maazen RW, de Witte TJ.

Ned Tijdschr Geneeskd. 1996 Oct 19;140(42):2087-91. Dutch.

PMID:
8965951
16.

Clonal predominance of cytomegalovirus-specific CD8+ cytotoxic T lymphocytes in bone marrow recipients.

Dolstra H, Van de Wiel-van Kemenade E, De Witte T, Preijers F.

Bone Marrow Transplant. 1996 Aug;18(2):339-45.

PMID:
8864444
17.

Expansion of CD8+CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection.

Dolstra H, Preijers F, Van de Wiel-van Kemenade E, Schattenberg A, Galama J, de Witte T.

Br J Haematol. 1995 Jun;90(2):300-7.

PMID:
7540855
18.

Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J, Figdor CG.

J Immunol. 1993 Jul 15;151(2):767-76.

PMID:
7687622
19.

Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells.

Danen EH, van Muijen GN, van de Wiel-van Kemenade E, Jansen KF, Ruiter DJ, Figdor CG.

Int J Cancer. 1993 May 8;54(2):315-21.

PMID:
8387465
20.

Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer.

Vlasveld LT, van de Wiel-van Kemenade E, de Boer AJ, Sein JJ, Gallee MP, Krediet RT, Mellief CJ, Rankin EM, Hekman A, Figdor CG.

Cancer Immunol Immunother. 1993;36(3):210-3.

PMID:
8439983
21.

Lymphocyte function-associated antigen 1 dominates very late antigen 4 in binding of activated T cells to endothelium.

van Kooyk Y, van de Wiel-van Kemenade E, Weder P, Huijbens RJ, Figdor CG.

J Exp Med. 1993 Jan 1;177(1):185-90.

22.

Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation.

Van de Wiel-van Kemenade E, Te Velde AA, De Boer AJ, Weening RS, Fischer A, Borst J, Melief CJ, Figdor CG.

Eur J Immunol. 1992 Jun;22(6):1467-75.

PMID:
1376259
23.

Adhesion of T and B lymphocytes to extracellular matrix and endothelial cells can be regulated through the beta subunit of VLA.

van de Wiel-van Kemenade E, van Kooyk Y, de Boer AJ, Huijbens RJ, Weder P, van de Kasteele W, Melief CJ, Figdor CG.

J Cell Biol. 1992 Apr;117(2):461-70.

24.

Role of LFA-1 and VLA-4 in the adhesion of cloned normal and LFA-1 (CD11/CD18)-deficient T cells to cultured endothelial cells. Indication for a new adhesion pathway.

Vennegoor CJ, van de Wiel-van Kemenade E, Huijbens RJ, Sanchez-Madrid F, Melief CJ, Figdor CG.

J Immunol. 1992 Feb 15;148(4):1093-101.

PMID:
1371131

Supplemental Content

Loading ...
Support Center